ID: ALA5219662

Max Phase: Preclinical

Molecular Formula: C187H309N57O47S

Molecular Weight: 4139.95

Associated Items:

Representations

Canonical SMILES:  CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C187H309N57O47S/c1-98(2)86-132(155(262)212-95-145(255)216-117(40-18-26-73-188)157(264)220-124(48-34-81-208-184(200)201)161(268)219-121(44-22-30-77-192)163(270)232-134(89-108-52-60-112(248)61-53-108)171(278)222-119(42-20-28-75-190)159(266)225-128(68-70-142(197)252)167(274)221-127(51-37-84-211-187(206)207)169(276)243-149(102(9)10)180(287)229-123(46-24-32-79-194)165(272)236-138(93-144(199)254)175(282)230-131(183(290)291)47-25-33-80-195)237-181(288)148(101(7)8)242-152(259)104(12)213-151(258)103(11)215-170(277)133(87-99(3)4)231-173(280)136(91-110-56-64-114(250)65-57-110)234-164(271)120(43-21-29-76-191)218-160(267)122(45-23-31-78-193)228-179(286)147(100(5)6)241-153(260)105(13)214-156(263)130(72-85-292)227-168(275)129(69-71-143(198)253)226-158(265)118(41-19-27-74-189)217-162(269)125(49-35-82-209-185(202)203)223-172(279)135(90-109-54-62-113(249)63-55-109)233-166(273)126(50-36-83-210-186(204)205)224-177(284)140(96-245)239-174(281)137(92-111-58-66-115(251)67-59-111)235-178(285)141(97-246)240-176(283)139(94-146(256)257)238-182(289)150(106(14)247)244-154(261)116(196)88-107-38-16-15-17-39-107/h15-17,38-39,52-67,98-106,116-141,147-150,245-251,292H,18-37,40-51,68-97,188-196H2,1-14H3,(H2,197,252)(H2,198,253)(H2,199,254)(H,212,262)(H,213,258)(H,214,263)(H,215,277)(H,216,255)(H,217,269)(H,218,267)(H,219,268)(H,220,264)(H,221,274)(H,222,278)(H,223,279)(H,224,284)(H,225,266)(H,226,265)(H,227,275)(H,228,286)(H,229,287)(H,230,282)(H,231,280)(H,232,270)(H,233,273)(H,234,271)(H,235,285)(H,236,272)(H,237,288)(H,238,289)(H,239,281)(H,240,283)(H,241,260)(H,242,259)(H,243,276)(H,244,261)(H,256,257)(H,290,291)(H4,200,201,208)(H4,202,203,209)(H4,204,205,210)(H4,206,207,211)/t103-,104-,105-,106+,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130+,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,147-,148-,149-,150-/m0/s1

Standard InChI Key:  HXROOIDQCQSPGK-DLOSMSPMSA-N

Associated Targets(Human)

ADCYAP1R1 Tchem Pituitary adenylate cyclase-activating polypeptide type I receptor (345 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
VIPR1 Tchem Vasoactive intestinal polypeptide receptor 1 (1904 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
VIPR2 Tchem Vasoactive intestinal polypeptide receptor 2 (744 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 4139.95Molecular Weight (Monoisotopic): 4137.3262AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Hu E, Hong FT, Aral J, Long J, Piper DE, Poppe L, Andrews KL, Hager T, Davis C, Li H, Wong P, Gavva N, Shi L, Zhu DXD, Lehto SG, Xu C, Miranda LP..  (2021)  Discovery of Selective Pituitary Adenylate Cyclase 1 Receptor (PAC1R) Antagonist Peptides Potent in a Maxadilan/PACAP38-Induced Increase in Blood Flow Pharmacodynamic Model.,  64  (6.0): [PMID:33715378] [10.1021/acs.jmedchem.0c01396]

Source